Sanofi-Aventis S.A. ADR (SNY)
$56.21
0.98 (1.77%)
SNY Stock Quote Delayed 30 Minutes
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
70.30B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2.18M
Day's Range
$55.56 - $56.32
52-Week Range
$42.63 - $56.32
Dividend & Yield
$1.90 (3.39%)
SNY Stock Predictions, Articles, and Sanofi-Aventis S.A. ADR News
10 Buffett Dividend Stocks Paying 3% or More
For lovers of Warren Buffett and dividends, this is the perfect storm -- a list of some of Buffett's portfolio picks that boast high yields.
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.
What Says the Investing All-Star Team?
Our panel of experts recently assembled to discuss the state of the markets and economy. Some thoughts may surprise you and some advise you. You get to pick.
5 Best Buffett Dividend Stocks
For dividend investors wondering what Warren Buffett thinks of income investments, here's a look at the five highest-yielding stocks in the Berkshire portfolio.
Pfizer is Still a Pharmaceutical-Giant Buy
Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio.
Survey: Americans Prefer Samsung Over Sony
A consumer survey finds that Samsung has eclipsed Sony's popularity among American HDTV buyers.
9 Pharma Buys for a Healthy Portfolio
Their dividends are attractive, and some drugmakers have made great progress in refilling their pipelines.
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.
10 Pharma Blue Chips to Buy
There are a number of great companies in pharma if you know where to look.
10 Pharma Stocks to Add to Your Portfolio…Stat
Investors have plenty of reasons to invest in the health care industry. With returns like these, it's no wonder investors are scrambling to own them.
Small Patient Population? Charge $400K a Year for Your Drug
Companies like BioMarin Pharmaceutical are cashing in on rare diseases, where they can charge hundreds of thousands of dollars every year for their drugs.
The Little Guys Are Pharma’s New Stars
Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules.
8 Pharma Stocks in Good Health
The health care sector is a field that will continue to grow as Baby Boomers get old and retire. These eight companies will be at the center of this trend.
RIMM Completes a Week of Gloomy Outlooks — Friday’s IP Market Recap
Research In Motion joined Intel, Best Buy and First Solar in forecasting leaner times ahead. Here's a look at RIM, as well as other big news from this week.
Covidien Follows Abbott With a Pharma Spin-Off
Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?
7 Feel-Good Pharma Stocks to Buy
Medicine is something few people can afford to go without during times of recession, making these pharma companies good sources of stability.
